So, you know how biotech stocks sometimes move on news that's a bit... technical? Well, Zevra Therapeutics (ZVRA) is having one of those days, but with a double dose of good news that investors seem to really like. The stock popped more than 20% in early trading Tuesday. Why? The company just teamed up with another player to make it easier to find patients for its rare disease drug, and it also reported quarterly numbers that were better than anyone expected.

Let's start with the partnership. Zevra is working with GeneDx Holdings Corp. (WGS) on genetic testing for Niemann-Pick Disease type C, or NPC. If you're not familiar, NPC is a nasty, inherited disorder where cholesterol and lipids build up in cells. It leads to severe neurological problems—think dementia, trouble with coordination, and eye movement issues—and often cuts lives short. There's no cure, so treatment is all about managing symptoms.

The goal here is pretty straightforward: find patients faster. GeneDx is launching a testing program to give more clinicians access to its ExomeDx test for suspected NPC cases. In simple terms, they're trying to remove some of the roadblocks that slow down diagnosis.

"Through our partnership with Zevra we are removing barriers to high-quality exome sequencing so clinicians can reach answers faster, confirm diagnoses with precision, and identify patients earlier," said Lisa Gurry, the chief business officer at GeneDx. She added that their programs are powered by "the world's largest rare-disease genomic dataset," which helps partners "better understand disease biology, and accelerate the patient journey from diagnosis to treatment."

For Zevra, which has a drug called MIPLYFFA for NPC, this is a smart move. If you can diagnose people more efficiently, you can potentially get them on therapy sooner. It's a classic play in rare disease biotech: you don't just develop the drug; you also try to build the ecosystem around it.

Now, the other piece of the puzzle: the financials. Zevra also dropped its fourth-quarter results, and they were solid. The company reported earnings of 19 cents per share. Wall Street analysts were only looking for 5 cents. Revenue came in at $34.1 million, comfortably above the $28.1 million estimate. As of the end of December 2025, the company was sitting on a cash pile of $62.4 million.

Neil F. McFarlane, Zevra's President and CEO, tied the performance back to the drug. "MIPLYFFA is making a meaningful difference for patients with Niemann-Pick disease type C, and its strong, accelerating performance reinforces our confidence in its long-term potential," he said. He also noted the company has officially moved its global headquarters to Boston, which he says will help them tap into a deeper talent pool.

"Looking ahead, we are focused on executing against multiple near-term growth opportunities in 2026, and believe we are well-positioned to execute on our strategic priorities to create meaningful value for the rare disease community and our shareholders," McFarlane added.

Put it all together, and you've got a stock moving on more than just hype. There's a concrete strategy to grow the business for its flagship drug and financial results that show it's working. At last check, Zevra shares were up about 21.7% to $10.93. Not a bad day's work.